“Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s373. doi:10.25251/skin.8.supp.373.